---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-127949"
form_type: "8-K"
ticker: "HOOK"
cik: "0001760542"
company_name: "HOOKIPA Pharma Inc."
filed_at: "2023-12-21T23:59:59+00:00"
generated_at: "2026-06-07T09:15:29.230437+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Gilead invests $21.25M in HOOKIPA for 15M shares at $1.4167 each

## Summary
- Gilead purchased 15M shares for ~$21.25M at $1.4167/share; now holds 19.4% of HOOK outstanding stock.
- HOOKIPA may sell up to $8.75M additional shares to Gilead in future equity raises under same agreement.
- Funds to advance HIV therapeutic vaccine HB-500 through Phase 1; trial expected to start H1 2024.
- Agreement replaces 2022 stock purchase agreement; total committed $30M now largely funded.

## SEC filing metadata
- accession: 0001104659-23-127949
- form_type: 8-K
- ticker: HOOK
- cik: 0001760542
- company_name: HOOKIPA Pharma Inc.
- filed_at: 2023-12-21T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 3.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1760542/000110465923127949/0001104659-23-127949-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1760542/000110465923127949/tm2333370d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-127949
- JSON: https://secwatch.observer/filing/0001104659-23-127949.json
- Plain text: https://secwatch.observer/filing/0001104659-23-127949.txt

## Key facts
- Material Agreements
  HOOKIPA Pharma Inc. amended Amended and Restated Stock Purchase Agreement with Gilead Sciences, Inc. valued at approximately $21.25 million (effective 2023-12-20).
  - Action: amendment
  - Agreement: equity purchase
  - Counterparty: Gilead Sciences, Inc.
  - Value: approximately $21.25 million
  - Effective: 2023-12-20
  source text: On December 20, 2023, (the “Effective Date”), HOOKIPA Pharma Inc. (the “Company”) entered into an Amended and Restated Stock Purchase Agreement (the “A&R Stock Purchase Agreement”) with Gilead Sciences, Inc. (“Gilead”), which amends and restates in its entirety the Company’s Stock Purchase Agreement, dated February 15, 2022, with Gilead, pursuant to which Gilead had purchased $5.0 million of the Company’s Common Stock and committed to purchase an additional $30.0 million.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1760542/000110465923127949/0001104659-23-127949-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.